X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs BIOCON LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA BIOCON LTD TORRENT PHARMA/
BIOCON LTD
 
P/E (TTM) x 27.2 82.9 32.9% View Chart
P/BV x 5.2 7.8 66.4% View Chart
Dividend Yield % 1.1 0.2 661.4%  

Financials

 TORRENT PHARMA   BIOCON LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
BIOCON LTD
Mar-17
TORRENT PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,162 152.1%   
Low Rs1,186483 245.7%   
Sales per share (Unadj.) Rs346.1194.6 177.9%  
Earnings per share (Unadj.) Rs55.234.4 160.4%  
Cash flow per share (Unadj.) Rs73.348.3 151.9%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %0.90.1 779.5%  
Book value per share (Unadj.) Rs257.1241.9 106.3%  
Shares outstanding (eoy) m169.22200.00 84.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.2 101.0%   
Avg P/E ratio x26.823.9 112.0%  
P/CF ratio (eoy) x20.117.0 118.3%  
Price / Book Value ratio x5.73.4 169.0%  
Dividend payout %25.42.9 873.1%   
Avg Mkt Cap Rs m249,887164,440 152.0%   
No. of employees `00011.89.2 127.6%   
Total wages/salary Rs m9,9347,470 133.0%   
Avg. sales/employee Rs Th4,971.54,213.9 118.0%   
Avg. wages/employee Rs Th843.2809.0 104.2%   
Avg. net profit/employee Rs Th792.4745.2 106.3%   
INCOME DATA
Net Sales Rs m58,56938,911 150.5%  
Other income Rs m2,2331,571 142.1%   
Total revenues Rs m60,80240,482 150.2%   
Gross profit Rs m13,7739,795 140.6%  
Depreciation Rs m3,0692,772 110.7%   
Interest Rs m2,056260 790.6%   
Profit before tax Rs m10,8818,334 130.6%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,616 95.6%   
Profit after tax Rs m9,3366,881 135.7%  
Gross profit margin %23.525.2 93.4%  
Effective tax rate %14.219.4 73.2%   
Net profit margin %15.917.7 90.1%  
BALANCE SHEET DATA
Current assets Rs m53,84140,477 133.0%   
Current liabilities Rs m31,61216,783 188.4%   
Net working cap to sales %38.060.9 62.3%  
Current ratio x1.72.4 70.6%  
Inventory Days Days9760 163.0%  
Debtors Days Days8483 101.1%  
Net fixed assets Rs m42,07945,073 93.4%   
Share capital Rs m8461,000 84.6%   
"Free" reserves Rs m42,65547,377 90.0%   
Net worth Rs m43,50148,377 89.9%   
Long term debt Rs m22,40821,082 106.3%   
Total assets Rs m101,25093,942 107.8%  
Interest coverage x6.333.1 19.0%   
Debt to equity ratio x0.50.4 118.2%  
Sales to assets ratio x0.60.4 139.7%   
Return on assets %11.37.6 148.0%  
Return on equity %21.514.2 150.9%  
Return on capital %19.612.6 155.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06612,988 154.5%   
Fx outflow Rs m5,3047,899 67.1%   
Net fx Rs m14,7625,089 290.1%   
CASH FLOW
From Operations Rs m10,1276,400 158.2%  
From Investments Rs m-7,869-4,985 157.9%  
From Financial Activity Rs m-1,918-1,775 108.1%  
Net Cashflow Rs m212-473 -44.7%  

Share Holding

Indian Promoters % 71.5 40.4 177.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.0 8.4 83.6%  
FIIs % 12.6 10.7 117.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.9 44.2%  
Shareholders   26,511 109,995 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SUVEN LIFE COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS